To the Editor I write to amend my disclosures of potential conflicts of interest in articles1-11 published in JAMA Oncology in 2016 through 2018. In 1 of these articles, “Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial,”8 which represented a clinical trial of a novel therapeutic in patients with gastric cancer, I reported relevant disclosures related to consulting work with the biotechnology and pharmaceutical industry focused on cancer drug development as follows: “Dr Fuchs has been a consultant for Eli Lilly, Entrinsic Health, Pfizer, Merck, Sanofi, Roche, Genentech, Merrimack Pharmaceuticals, Dicerna, Bayer, Agios, Gilead Sciences, Five Prime Therapeutics, and Taiho.” However, that disclosure did not include my relationships at the time with Celgene and KEW. The other studies assessed the role of obesity, diet, lifestyle habits, and genetic mutations in cancer risk and outcome,1-7,9-11 and for those articles I reported that I had no potential conflicts of interest to disclosure. With respect to these analyses of obesity, diet, lifestyle habits, and genetic mutations and cancer, I did not consider that my consulting work in drug development represented a potential conflict of interest or a relevant financial activity to the submitted works. Additionally, I did not believe that my consulting work would be perceived by readers to have influenced or give the appearance of potentially influencing analyses of obesity, diet, lifestyle habits, and genetic mutations in cancer risk and outcome.
Fuchs CS. Omitted Disclosures of Potential Conflicts of Interest in Articles Published in JAMA Oncology. JAMA Oncol. 2019;5(4):578–579. doi:10.1001/jamaoncol.2019.0235
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.